NCT07387471 2026-03-16
Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
AbbVie
Phase 2 Recruiting
Clinical Trials
18 trialsNCT04849416 2026-02-06
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company
Phase 2 Completed
NCT04116437 2026-01-28
Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment
BeOne Medicines
Phase 2 Completed
NCT03105336 2025-12-23
ZUMA-5
Gilead Sciences
Phase 2 Completed
NCT04245839 2025-11-05
TRANSCEND FL
Celgene
Phase 2 Active not recruiting
NCT03888105 2025-10-15
ELM-2
Regeneron Pharmaceuticals
Phase 2 Active not recruiting
NCT03144674 2025-07-11
A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
Incyte Corporation
Phase 2 Completed
NCT04849351 2025-04-06
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Hutchmed
Phase 2 Completed
NCT03768505 2024-12-31
Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)
MEI Pharma, Inc.
Phase 2 Terminated
NCT05008055 2024-12-20
CAPITAL
AstraZeneca
Phase 2 Completed
NCT03520920 2024-10-26
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
BeiGene
Phase 2 Completed
NCT03846427 2024-10-26
MAGNOLIA
BeiGene
Phase 2 Completed
NCT04298879 2024-06-05
IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT00081809 2023-09-28
A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma
Agenus Inc.
Phase 2 Completed
NCT03364231 2023-06-23
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
TG Therapeutics, Inc.
Phase 2 Completed
NCT04431089 2021-01-28
Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) Lymphoma
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Phase 2 Unknown
NCT01980628 2019-10-16
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma
Pharmacyclics LLC.
Phase 2 Completed
NCT01282424 2019-07-11
DELTA
Gilead Sciences
Phase 2 Completed